Notice: This company has been marked as potentially delisted and may not be actively trading. Talaris Therapeutics (TALS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsDividendInsider TradesTrends TALS vs. MESO, CALT, STML, NAUT, FULC, CRSP, IMVT, IBRX, DNLI, and VCELShould you be buying Talaris Therapeutics stock or one of its competitors? The main competitors of Talaris Therapeutics include Mesoblast (MESO), Calliditas Therapeutics AB (publ) (CALT), Stemline Therapeutics (STML), Nautilus Biotechnology (NAUT), Fulcrum Therapeutics (FULC), CRISPR Therapeutics (CRSP), Immunovant (IMVT), ImmunityBio (IBRX), Denali Therapeutics (DNLI), and Vericel (VCEL). These companies are all part of the "medical" sector. Talaris Therapeutics vs. Mesoblast Calliditas Therapeutics AB (publ) Stemline Therapeutics Nautilus Biotechnology Fulcrum Therapeutics CRISPR Therapeutics Immunovant ImmunityBio Denali Therapeutics Vericel Mesoblast (NASDAQ:MESO) and Talaris Therapeutics (NASDAQ:TALS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation, risk and community ranking. Do analysts prefer MESO or TALS? Mesoblast presently has a consensus price target of $11.50, suggesting a potential upside of 12.97%. Given Mesoblast's stronger consensus rating and higher probable upside, analysts clearly believe Mesoblast is more favorable than Talaris Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesoblast 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Talaris Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, MESO or TALS? Mesoblast has a beta of 3.47, meaning that its share price is 247% more volatile than the S&P 500. Comparatively, Talaris Therapeutics has a beta of 2.18, meaning that its share price is 118% more volatile than the S&P 500. Which has stronger earnings & valuation, MESO or TALS? Talaris Therapeutics has lower revenue, but higher earnings than Mesoblast. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMesoblast$5.90M197.01-$87.96MN/AN/ATalaris TherapeuticsN/AN/A-$73.89M-$1.79-13.41 Does the MarketBeat Community favor MESO or TALS? Mesoblast received 396 more outperform votes than Talaris Therapeutics when rated by MarketBeat users. Likewise, 70.27% of users gave Mesoblast an outperform vote while only 48.15% of users gave Talaris Therapeutics an outperform vote. CompanyUnderperformOutperformMesoblastOutperform Votes40970.27% Underperform Votes17329.73% Talaris TherapeuticsOutperform Votes1348.15% Underperform Votes1451.85% Do insiders & institutionals believe in MESO or TALS? 1.4% of Mesoblast shares are owned by institutional investors. Comparatively, 67.6% of Talaris Therapeutics shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by company insiders. Comparatively, 16.5% of Talaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media prefer MESO or TALS? In the previous week, Mesoblast had 5 more articles in the media than Talaris Therapeutics. MarketBeat recorded 5 mentions for Mesoblast and 0 mentions for Talaris Therapeutics. Mesoblast's average media sentiment score of 0.54 beat Talaris Therapeutics' score of 0.00 indicating that Mesoblast is being referred to more favorably in the media. Company Overall Sentiment Mesoblast Positive Talaris Therapeutics Neutral Is MESO or TALS more profitable? Mesoblast's return on equity of 0.00% beat Talaris Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets MesoblastN/A N/A N/A Talaris Therapeutics N/A -39.93%-37.37% SummaryMesoblast beats Talaris Therapeutics on 12 of the 14 factors compared between the two stocks. Ad WealthPressBreaking News: Tesla headed to $500…That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. Get Talaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TALS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TALS vs. The Competition Export to ExcelMetricTalaris TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.03B$2.98B$5.09B$8.81BDividend YieldN/A1.91%5.04%4.07%P/E Ratio-13.4118.9994.6014.18Price / SalesN/A286.511,217.5288.10Price / CashN/A169.3839.4936.27Price / Book5.544.416.956.35Net Income-$73.89M-$41.63M$118.83M$225.71M Talaris Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TALSTalaris TherapeuticsN/A$24.00+2.1%N/A+33.1%$1.03BN/A-13.4184MESOMesoblast1.3695 of 5 stars$10.18-1.5%$11.50+13.0%+345.3%$1.16B$5.90M0.0080Gap DownCALTCalliditas Therapeutics AB (publ)0.2585 of 5 stars$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180Positive NewsSTMLStemline TherapeuticsN/A$11.83flatN/A+0.0%$621.21M$43.22M-6.4692NAUTNautilus Biotechnology1.7627 of 5 stars$2.36+0.9%$4.50+90.7%-15.8%$296.32MN/A0.00130FULCFulcrum Therapeutics3.5645 of 5 stars$3.05+2.0%$9.33+206.0%-35.7%$164.52M$2.81M0.00100Analyst RevisionNews CoverageCRSPCRISPR Therapeutics1.788 of 5 stars$46.72-1.1%$74.94+60.4%-34.5%$3.99B$371.21M-16.31473IMVTImmunovant1.5501 of 5 stars$26.64+1.8%$48.10+80.6%-22.6%$3.91BN/A0.00120IBRXImmunityBio0.7381 of 5 stars$5.11+4.7%$4.75-7.0%+20.4%$3.56B$620,000.000.00590Positive NewsDNLIDenali Therapeutics4.4645 of 5 stars$24.38-0.2%$38.90+59.6%+27.3%$3.51B$330.53M0.00364VCELVericel1.1053 of 5 stars$58.30+1.8%$58.14-0.3%+56.1%$2.88B$197.52M954.49300Analyst Forecast Related Companies and Tools Related Companies Mesoblast Alternatives Calliditas Therapeutics AB (publ) Alternatives Stemline Therapeutics Alternatives Nautilus Biotechnology Alternatives Fulcrum Therapeutics Alternatives CRISPR Therapeutics Alternatives Immunovant Alternatives ImmunityBio Alternatives Denali Therapeutics Alternatives Vericel Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TALS) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Talaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Talaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
